Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin

Annals of Thoracic Surgery

Volumn 102, Issue 2, 2016, Pages 534-539

  Lim, Ju Yong ^a   Kim, Joon Bum ^a   Choo, Suk Jung ^a   Chung, Cheol Hyun ^a   Lee, Jae Won ^a   Jung, Sung Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEPARIN; NAFAMSTAT MESILATE; ANTICOAGULANT AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; EXTRACORPOREAL OXYGENATION; FEMALE; HEART FAILURE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENESCENCE; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING; DOSE RESPONSE; INTRAOPERATIVE PERIOD;

ANTICOAGULANTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; GUANIDINES; HEPARIN; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 84964380890     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2016.01.044     Document Type: Article

References (21)

1. 1 Green, T.P., Payne, N.R., Steinhorn, R.H., Determinants of blood product use during extracorporeal membrane–oxygenation. Transfusion 30 (1990), 289–290.
2. 2 Haines, N.M., Rycus, P.T., Zwischenberger, J.B., Bartlett, R.H., Undar, A., Extracorporeal Life Support Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J 55 (2009), 111–116.
3. 3 Nagaya, M., Futamura, M., Kato, J., Niimi, N., Fukuta, S., Application of a new anticoagulant (nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation––a preliminary report. J Pediatr Surg 32 (1997), 531–535.
4. 4 Han, S.J., Kim, H.S., Kim, K.I., et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci 26 (2011), 945–950.
5. 5 D'Agostino, R.B., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998), 2265–2281.
6. 6 Rosenbaum, P.R., Rubin, D.B., The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
7. 7 Horbett, T.A., Principles underlying the role of adsorbed plasma–proteins in blood interactions with foreign materials. Cardiovasc Pathol 2 (1993), S137–S148.
8. 8 Fortenberry, J.D., Bhardwaj, V., Niemer, P., Cornish, J.D., Wright, J.A., Bland, L., Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr 128 (1996), 670–678.
9. 9 Annich, G., Cornell, T., Massicotte, M., Lequier, L., Blood biomaterial surface interaction during ECLS. Annich, G., Lynch, W., MacLaren, G., Wilson, J., Bartlett, R., (eds.) Extracorporeal cardiopulmonary support in critical care, 4th ed., 2012, Extracorporeal Life Support Organization, Michigan, MI, 78–82.
10. 10 Hitomi, Y., Ikari, N., Fujii, S., Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15 (1985), 164–168.
11. 11 Fuse, I., Higuchi, W., Toba, K., Aizawa, Y., Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets 10 (1999), 212–218.
12. 12 Fujii, S., Yokoyama, T., Ikegaya, K., Yokoo, N., New synthetic inhibitors of chymotrypsin. J Biochem 95 (1984), 319–322.
13. 13 Aoyama, T., Ino, Y., Ozeki, M., et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35 (1984), 203–227.
14. 14 Koshiyama, Y., Ozeki, M., Motoyoshi, A., Fujita, M., Iwaki, M., Aoyama, T., Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nihon Yakurigaku Zasshi 84 (1984), 417–428.
15. 15 Hwang, S.D., Hyun, Y.K., Moon, S.J., Lee, S.C., Yoon, S.Y., nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 36 (2013), 208–216.
16. 16 Yang, J.W., Han, B.G., Kim, B.R., et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail 31 (2009), 668–675.
17. 17 Kotani, K., Ichiba, S., Andou, M., et al. Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 124 (2002), 626–627.
18. 18 Hiramatsu, Y., Homma, S., Sato, Y., et al. nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation. Ann Thorac Surg 79 (2005), 1326–1332.
19. 19 Kaminishi, Y., Hiramatsu, Y., Watanabe, Y., Yoshimura, Y., Sakakibara, Y., Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg 77 (2004), 644–650.
20. 20 Sakamoto, T., Kano, H., Miyahara, S., et al. Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke. J Heart Valve Dis 23 (2014), 744–751.
21. 21 Sundaram, S., Gikakis, N., Hack, C.E., et al. nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 75 (1996), 76–82.